Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arctigenin
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Arctigenin is a lignan extracted from *Arctium lappa* (burdock) with anti-inflammatory, antioxidant, antiviral, antibacterial, and antitumor properties. It inhibits nuclear factor-kappa B (NF-κB) activation, reducing pro-inflammatory cytokines and mediating oxidative stress pathways. Arctigenin also exhibits estrogenic properties and has been studied for its potential in cancer prevention and treatment.
- Other names
- (-)-ArctigeninUNII-U76MR9VS6MUNII-U-76MR9VS6MUNII-U 76MR9VS6M
02
Targets
NF-κBIL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)ADIPOR1 (Adiponectin receptor 1)
Beyond the preview
Go deeper on arctigenin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arctigenin.